Rapid Dose Therapeutics disrupts the cannabis market with QuickStrip™ technology
By Don Hauka
• Rapid Dose Therapeutics is well positioned to take advantage of the nutraceutical, cannabis and pharma markets with its QuickStrip™ technology
• Active molecules are released from the QuickStrip™ and are rapidly delivered into the bloodstream
• QuickStrip™ offers cannabis consumers a Smoke-Free Choice™
Cannabis – the next disruptor
The next big disruptor has arrived. Much like the end of Prohibition in the 1930s, the legalization of cannabis is sending shockwaves through markets, businesses, societies, pharmaceutical spaces, and other sectors.
With historical legalization completed, how can an investor take advantage of the start of a new disruptive cycle with so much uncertainty and so many variables at play?
It helps if you look for a company that has anticipated the wave and is on the cutting edge of it — specifically, one that has products that not only take advantage of the cannabis disruption but also has a product that transcends into multiple other sectors.
RDT’s QuickStrip™ technology — disruptor in its own right
Rapid Dose Therapeutics Inc. (CSE: DOSE) CEO, Mark Upsdell believes that he has positioned his company to do just that. His Canadian biotechnology company provides disruptive proprietary drug delivery technologies designed to improve patient outcomes. RDT’s goal is to move drug delivery to a new level and provide Quick, Convenient, Precise and Discreet™ dosing.
RDT is a service provider for the cannabis industry and has signed definitive agreements with licenced growers in the United States, Canada, European Union and Puerto Rico. This also includes signing with Aphria, one of the largest global cannabis producers. RDT owns and licenses its proprietary manufacturing equipment and medical delivery technology as a Managed Strip Service (MSS). The company’s service-based annuity contracts drive recurring revenue which enables rapid expansion into emerging markets — generating value for consumers and shareholders.
Timing is everything, and RDT is creating a lucrative opportunity for licensed producers and growers in the cannabis sector to provide a Smoke-Free Choice™ to cannabis consumers.
“What we’ve seen in the cannabis space is very similar to what happened when Prohibition ended, which is very instructive. So, I think from a company perspective we’re well positioned to take advantage of future growth in this cycle,” — Mark Upsdell, CEO, Rapid Dose Therapeutics Inc.
QuickStrip™ — how it works
RDT has developed a smoke-free drug-delivery system called QuickStrip™, which is a thin film strip designed to dissolve under the tongue (sublingually) or between the cheek and gum (buccal). These thin film strips can deliver not only cannabis products but also pharmaceuticals, nutraceuticals, and other therapeutic products.
What makes this technology unique is that QuickStrip™ delivers the active ingredient directly into the bloodstream in a precisely measured dose and bypasses the gastrointestinal tract. This delivery method dramatically boosts bioavailability and promotes the rapid onset of a drug on board — providing patients with quick results.
“The buccal mucosa, inside lining of the cheeks and mouth, contains tissue that is designed to allow the passing of products into the bloodstream,” says RDT’s VP of Business Development, Jason Lewis.
“The problem in healthcare has been to find a way to deliver drugs across those membranes effectively, and we’ve solved this with QuickStrip™.”
The sublingual and buccal delivery system is made possible by RDT’s protected micronizing technology that reduces the product to a size where it can pass through the tissue barrier.
Applications for QuickStrip™ technology are almost unlimited
The potential to expand the company’s three product divisions are almost unlimited. For instance, the nutraceutical division includes QuickStrips™ for vitamin B12 for overall health, melatonin for restful sleep, and caffeine for energy while the cannabis division works with LPs to provide THC and CBD products. The pharmaceutical division also has a wide range of products in development.
“I’ve been involved with the pharmaceutical industry for 30 years, and it’s been a long time since I’ve seen something that’s going to change the market like this. QuickStrip™ is a real game changer,” says Lewis.
He also notes that while cannabis might be the focus of attention right now, it’s the pharmaceuticals that will have the most significant impact on improving patient outcomes.
“If you think of a patient who has dysphagia, trouble swallowing, they have few alternatives like patches or injections, but neither are preferred options. It is time to deliver medication in a new and effective way, with the focus on improving patient outcomes” says Lewis.
How vast are the possibilities for the application of this technology? For starters, QuickStrip™ was recently awarded the “Top Ten in Grocery” award for the non-food category at Grocery Innovations Canada in Toronto. QuickStrip™ was also spotlighted at the New Product Showcase, which features the latest in industry innovations.
RDT public on CSE: DOSE
As of Monday, December 17th, 2018, RDT was publicly listed on the CSE and is preparing to launch its product lines. Upsdell says the company is well-capitalized and has assembled a strong team to take them to the next level.
“We have an opportunity to do many things from an R&D perspective. We will continue to expand into the health and wellness marketplace as we go forward. We have the right ingredients to propel RDT — the facility to expand, strategic relationships, R&D and the capital to grow the business and revolutionize drug delivery.”